SEARCH

SEARCH BY CITATION

References

  • 1
    Williams DL. Overview of (1–3)-beta-D-glucan immunobiology. Med Inflamm 1997; 6: 24750.
  • 2
    Seljelid R. Immunomodulators − medicine for the 90-ies? In: WadstrømT, EliassonI, HolderI, eds. Immunomodulators − medicine for the 90-ies? London: Springer Verlag, 1990: 10713.
  • 3
    Engstad RE, Robertsen B. Effect of structurally different beta-glucans on immune responses in Atlantic salmon. J Mar Biotech 1995; 3: 2037.
  • 4
    Bohn JA, BeMiller JN. (1–3)-beta-D-glucans as biologigal response modifiers: a review of structure–function relationships. Carbohydr Polym 1995; 28: 314.
  • 5
    Brown GD, Herre J, Williams DL et al. Dectin-1 mediates the biological effects of beta-glucans. J Exp Med 2003; 197: 111924.
  • 6
    Herre J, Gordon S, Brown GD. Dectin-1 and its role in the recognition of beta-glucans by macrophages. Mol Immunol 2004; 40: 86976.
  • 7
    Gantner BN, Simmons RM, Canavera SJ et al. Collaborative induction of inflammatory responses by dectin-1 and Toll-like receptor 2. J Exp Med 2003; 197: 110717.
  • 8
    Herre J, Marshall AS, Caron E et al. Dectin-1 uses novel mechanisms for yeast phagocytosis in macrophages. Blood 2004; 104: 403845.
  • 9
    Kikuchi T, Ohno N, Ohno T. Maturation of dendritic cells induced by Candida beta-D-glucan. Int Immunopharmacol 2002; 2: 15038.
  • 10
    Cheung NK, Modak S, Vickers A et al. Orally administered beta-glucans enhance anti-tumor effects of monoclonal antibodies. Cancer Immunol Immunother 2002; 51: 55764.
  • 11
    Wakshull E, Brunke-Reese D, Lindermuth J et al. PGG-glucan, a soluble beta-(1,3)-glucan, enhances the oxidative burst response, microbicidal activity, and activates an NF-kappa B-like factor in human PMN: evidence for a glycosphingolipid beta-(1,3)-glucan receptor. Immunopharmacology 1999; 41: 89107.
  • 12
    Kernodle DS, Gates H, Kaiser AB. Prophylactic anti-infective activity of poly-[1–6]-beta-D-glucopyranosyl-[1–3]-beta-D-glucopryanose glucan in a guinea pig model of staphylococcal wound infection. Antimicrob Agents Chemother 1998; 42: 5459.
  • 13
    Dellinger EP, Babineau TJ, Bleicher P et al. Effect of PGG-glucan on the rate of serious postoperative infection or death observed after high-risk gastrointestinal operations. Betafectin Gastrointestinal Study Group. Arch Surg 1999; 134: 97783.
  • 14
    Raa J, Berstad AKH, Bakke H et al. Novel, non-antigenic, mucosal adjuvant formulation which modulates the effects of substances, including vaccine antigens, in contact with mucosal body surfaces. 2000; WO0162283, Available at: http://ep.espacenet.com (accessed 30 August 2001).
  • 15
    Wei D, Williams D, Browder W. Activation of AP-1 and SP1 correlates with wound growth factor gene expression in glucan-treated human fibroblasts. Int Immunopharmacol 2002; 2: 116372.
  • 16
    Delatte SJ, Evans J, Hebra A et al. Effectiveness of beta-glucan collagen for treatment of partial-thickness burns in children. J Pediatr Surg 2001; 36: 1138.
  • 17
    Portera CA, Love EJ, Memore L et al. Effect of macrophage stimulation on collagen biosynthesis in the healing wound. Am Surg 1997; 63: 12531.
  • 18
    Hofer M, Pospisil M. Glucan as stimulator of hematopoiesis in normal and gamma-irradiated mice. A survey of the authors’ results. Int J Immunopharmacol 1997; 19: 6079.
  • 19
    Patchen ML, DiLuzio NR, Jacques P et al. Soluble polyglycans enhance recovery from cobalt-60-induced hemopoietic injury. J Biol Response Mod 1984; 3: 62733.
  • 20
    Patchen ML, D’Alesandro MM, Brook I et al. Glucan: mechanisms involved in its ‘radioprotective’ effect. J Leukoc Biol 1987; 42: 95105.
  • 21
    Burgaleta C, Golde DW. Effect of glucan on granulopoiesis and macrophage genesis in mice. Cancer Res 1977; 37: 173942.
  • 22
    Niskanen EO, Burgaleta C, Cline MJ et al. Effect of glucan, a macrophage activator, on murine hemopoietic cell proliferation in diffusion chambers in mice. Cancer Res 1978; 38: 14069.
  • 23
    Turnbull JL, Patchen ML, Scadden DT. The polysaccharide, PGG-glucan, enhances human myelopoiesis by direct action independent of and additive to early-acting cytokines. Acta Haematol 1999; 102: 6671.
  • 24
    De Felippe Junior J, Da Rocha e Silva Junior M, Maciel FM et al. Infection prevention in patients with severe multiple trauma with the immunomodulator beta 1-3 polyglucose (glucan). Surg Gynecol Obstet 1993; 177: 3838.
  • 25
    Li C, Ha T, Kelley J et al. Modulating Toll-like receptor mediated signaling by (1–3)-beta-D-glucan rapidly induces cardioprotection. Cardiovasc Res 2004; 61: 53847.
  • 26
    Soltys J, Quinn MT. Modulation of endotoxin- and enterotoxin-induced cytokine release by in vivo treatment with beta-(1,6)-branched beta-(1,3)-glucan. Infect Immun 1999; 67: 24452.
  • 27
    Bowers GJ, Patchen ML, MacVittie TJ et al. Glucan enhances survival in an intraabdominal infection model. J Surg Res 1989; 47: 1838.
  • 28
    Liang J, Melican D, Cafro L et al. Enhanced clearance of a multiple antibiotic resistant Staphylococcus aureus in rats treated with PGG-glucan is associated with increased leukocyte counts and increased neutrophil oxidative burst activity. Int J Immunopharmacol 1998; 20: 595614.
  • 29
    Babineau TJ, Hackford A, Kenler A et al. A phase II multicenter, double-blind, randomized, placebo-controlled study of three dosages of an immunomodulator (PGG-glucan) in high-risk surgical patients. Arch Surg 1994; 129: 120410.
  • 30
    Saeki F, Ridge RJ, Finkelman MA et al. Application of a glucan-specific Limulus amebocyte lysate serum assay for diagnosis of invasive fungal infections. Proceedings of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, 2001, p. 386.
  • 31
    Odabasi Z, Mattiuzzi G, Estey E et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004; 39: 199205.
  • 32
    Elguezabal N, Maza JL, Pontón J. Inhibition of adherence of Candida albicans and Candida dubliniensis to a resin composite restorative dental material by salivary secretory IgA and monoclonal antibodies. Oral Dis 2004; 10: 816.
  • 33
    Tanida T, Okamaoto T, Okamoto A et al. Decreased excretion of antimicrobial proteins and peptides in saliva of patients with oral candidiasis. J Oral Pathol Med 2003; 32: 58694.
  • 34
    Shkalim V, Monselise Y, Mosseri R et al. Recurrent parotitis in selective IgA deficiency. Pediatr Allergy Immunol 2004; 18: 2813.